MGCL.F Stock Overview
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.28 |
| 52 Week High | AU$6.90 |
| 52 Week Low | AU$0.23 |
| Beta | 0.98 |
| 1 Month Change | -5.08% |
| 3 Month Change | n/a |
| 1 Year Change | -95.56% |
| 3 Year Change | -99.38% |
| 5 Year Change | -99.22% |
| Change since IPO | -99.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| MGCL.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -1.7% |
| 1Y | -95.6% | 11.5% | 22.4% |
Return vs Industry: MGCL.F underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: MGCL.F underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| MGCL.F volatility | |
|---|---|
| MGCL.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MGCL.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MGCL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Roby Zomer | mgcpharma.com.au |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
| MGCL.F fundamental statistics | |
|---|---|
| Market cap | US$13.01m |
| Earnings (TTM) | -US$10.99m |
| Revenue (TTM) | US$855.43k |
15.2x
P/S Ratio-1.2x
P/E RatioIs MGCL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGCL.F income statement (TTM) | |
|---|---|
| Revenue | AU$1.32m |
| Cost of Revenue | AU$1.20m |
| Gross Profit | AU$125.39k |
| Other Expenses | AU$17.14m |
| Earnings | -AU$17.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 9.47% |
| Net Profit Margin | -1,284.89% |
| Debt/Equity Ratio | 1,366.5% |
How did MGCL.F perform over the long term?
See historical performance and comparison